Over and underestimation of Lp(a) due to its different molecular weight isoforms has led to bias in many studies leading to underestimation of its strength as a cardiovascular risk factor.
Find out more on our HEART UK conference pages. The Health Professional area of the website is intended only for healthcare professionals.
This event is intended for healthcare professionals from the UK and receives sponsorship from pharmaceutical companies
Prof Steve HUMPHRIES will be presenting at the HEART UK conference on Wednesday 7th July.
How knowing that a patient with clinical FH has a polygenic and not a monogenic cause for their phenotype is key in the clinician deciding on the appropriate patient care pathway.
Find out more on our HEART UK conference pages. The Health Professional area of the website is intended only for healthcare professionals.
This event is intended for healthcare professionals from the UK and receives sponsorship from pharmaceutical companies
In the absence of evidence from a high-quality clinical trial, a consensus statement by HEART UK provides a guide for managing hyperlipidaemia during the pandemic, based on available evidence and experts’ opinion.
Historically a ketogenic diet was used to treat epilepsy in children. More recently, it has become popular as a way to lose weight and manage Type II Diabetes. We take a look at its effect on weight and cardiometabolic risk factors.
Recently low carbohydrate and very low carbohydrate diets have been used for weight loss and have been promoted for type 2 diabetes management. The main mode of action is likely to be the reduction in energy intake associated with carbohydrate restriction.
Recently non-HDL cholesterol has been recommended to replace LDL cholesterol in the clinical management of dyslipidaemia routinely in general medical practice. The authors claim this is misguided.
Research suggests adherence to lifelong pharmacological and lifestyle treatment by people with FH is poor. This study explores the qualitative research to identify enablers and barriers to treatment adherence.
To describe demographic characteristics, current local clinical management and outcomes for patients with familial hypercholesterolaemia (FH) managed at the Royal Brompton and Harefield NHS Foundation Trust (RBHT), a specialist UK tertiary cardiac centre.
Source: Journal of Clinical Lipidology and Metabolic Disorders
Familial chylomicronemia syndrome is a rare genetic disorder that is caused by loss of lipoprotein lipase activity and characterized by chylomicronemia and recurrent episodes of pancreatitis. There are no effective therapies. In an open-label study of three patients with this syndrome, antisense-mediated inhibition of hepatic APOC3 mRNA with volanesorsen led to decreased plasma apolipoprotein C-III and triglyceride levels.
